Microport Cardioflow Completes $324 Million HK IPO for Heart Valve Devices

Shanghai Microport Cardioflow Medtech, a spinout from China medical device maker Microport, completed a $324 million IPO in Hong Kong . Cardioflow develops transcatheter aortic valve implantation (TAVI) products that replace defective heart valves through a minimally invasive procedure. Its Vitaflow product, the first China TAVI device to use bovine pericardium as valve tissue, was approved for China use in 2019. The company is working on bringing Vitaflow to global markets. Cardioflow is trading 59% above its IPO price at a market capitalization of $6 billion. More details.... Stock Symbols: (HK: 2160) (HK: 0853) Share this with colleagues: // //